Study of the Efficiency of the Hydroporation for Delivery of Plasmid DNA to the Cells on the Model of Toxic Neuropathy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

We compared the efficiency of delivery of plasmid DNA (active ingredient concentration 1 mg/kg) that provides production of nerve growth factor (NGF) after intravenous administration to rats and after administration by hydroporation. The method of hydroporation ensured plasmid penetration into the liver tissue and lengthened the time of its detection in the organ. DNA concentration in 1 h after its introduction by hydroporation or intravenous route was 0.7 and 0.05 ng/mg tissue, respectively. The use of this transfection method ensured preservation of NGF DNA in the liver tissue at a level of 0.24 ng/mg of tissue 1 day after administration of the plasmid construct, while after intravenous administration, expression of the analyzed DNA was not detected in blood and liver samples. After hydroporation, the maximum of relative normalized expression of cDNA (270 rel. units) was observed after 4 h, and after 1 day, this parameter decreased to 35 rel. units. Introduction of plasmid DNA of NGF by hydroporation prevented the development of disorders of neuromuscular conduction in a rats model of toxic neuropathy induced by subacute administration of malathion in a dose of 0.5 LD50.

About the authors

M. A. Yudin

State Research Testing Institute of Military Medicine, Ministry of Defense of the Russian Federation

Author for correspondence.
Email: gniii_vm2@mil.ru
Russian Federation, St. Petersburg

V. N. Bykov

State Research Testing Institute of Military Medicine, Ministry of Defense of the Russian Federation

Email: gniii_vm2@mil.ru
Russian Federation, St. Petersburg

A. S. Nikiforov

State Research Testing Institute of Military Medicine, Ministry of Defense of the Russian Federation

Email: gniii_vm2@mil.ru
Russian Federation, St. Petersburg

R. I. Al-Shekhadat

InnovaBio Company

Email: gniii_vm2@mil.ru
Russian Federation, St. Petersburg

I. M. Ivanov

State Research Testing Institute of Military Medicine, Ministry of Defense of the Russian Federation

Email: gniii_vm2@mil.ru
Russian Federation, St. Petersburg

T. M. Ustinova

State Research Testing Institute of Military Medicine, Ministry of Defense of the Russian Federation

Email: gniii_vm2@mil.ru
Russian Federation, St. Petersburg


Copyright (c) 2018 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies